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Botulinum neurotoxin type A (BoNT/A) paralyses muscles by blocking acetylcholine (ACh)
release from motor nerve terminals. Although highly toxic, it is used clinically to weaken
muscles whose contraction is undesirable, as in dystonias. The effects of an injection of BoNT/A
wear off after 3–4 months so repeated injections are often used. Recovery of neuromuscular
transmission is accompanied by the formation of motor axon sprouts, some of which form new
synaptic contacts. However, the functional importance of these new contacts is unknown. Using
intracellular and focal extracellular recording we show that in the mouse epitrochleoanconeus
(ETA), quantal release from the region of the original neuromuscular junction (NMJ) can be
detected as soon as from new synaptic contacts, and generally accounts for > 80% of total
release. During recovery the synaptic delay and the rise and decay times of endplate potentials
(EPPs) become prolonged approximately 3-fold, but return to normal after 2–3 months. When
studied after 3–4 months, the response to repetitive stimulation at frequencies up to 100 Hz is
normal. When two or three injections of BoNT/A are given at intervals of 3–4 months, quantal
release returns to normal values more slowly than after a single injection (11 and 15 weeks to
reach 50% of control values versus 6 weeks after a single injection). In addition, branching of the
intramuscular muscular motor axons, the distribution of the NMJs and the structure of many
individual NMJs remain abnormal. These findings highlight the plasticity of the mammalian
NMJ but also suggest important limits to it.
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Botulinum toxin A (BoNT/A) blocks signal transmission at
the vertebrate neuromuscular junction (NMJ). Although
highly toxic, it is used clinically in small doses which are
injected intramuscularly to inhibit undesirable muscular
contractions in various forms of dystonia and cerebral
palsy and also cosmetically to reduce facial wrinkling.
The blocking effect usually wears off after 3–4 months so
repeated injections are required, sometimes over a period
of years, to maintain the desired effect (Jankovic & Hallett,
1994; Dolly & Aoki, 2006). As many people are now being
treated with BoNT/A, it is clearly important to under-
stand both its short-, and long-term effects on muscle
innervation.
BoNT/A is a metalloendoprotease. After binding to the
synaptic vesicle protein SV2 at the surface of the motor
nerve terminal (Dong et al. 2006), it is internalized and
activated. It then specifically cleaves SNAP-25, an essential
protein in exocytosis, thus preventing the ‘quantal’ release
of ACh in response to nerve impulses (Schiavo et al. 2000).
During the period of recovery from BoNT/A, sprouts grow
out from the motor axon and may make contact with the
muscle fibre (Duchen, 1970; Angaut-Petit et al. 1990; de
Paiva et al. 1999; Santafe et al. 2000). Key synaptic proteins
are subsequently expressed at many of these sites (Duchen,
1970; Yee & Pestronk, 1987; Juzans et al. 1996b; de Paiva
et al. 1999). Although it is generally assumed that synaptic
transmission occurs at these new contacts and mediates
the initial functional recovery from BoNT/A (e.g. Molgo
et al. 1990; Angaut-Petit et al. 1990) we are unaware that
this view has ever been directly tested.
Some evidence concerning the role of new contacts
in the recovery from BoNT/A comes from a study in
which changes in the ability of identified NMJs to take up
the membrane soluble fluorescent dye FM1-43 (Cochilla
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et al. 1999) were studied in vivo at various times after
administering BoNT/A (de Paiva et al. 1999). Exposure
to BoNT/A blocked activity-dependent FM1-43 labelling
of the original nerve terminals within a few days. Newly
formed axonal sprouts were seen to take up FM1-43 at a
stage of recovery when uptake by the original terminal was
still undetectable. However, 2–3 months after intoxication,
the original terminal began to recover its ability to take
up the dye and the sprouts were then withdrawn. These
results were interpreted to mean that during the initial
stage of recovery the sprouts, which appeared to be the only
possible source of quantal ACh release, were exclusively
responsible for the initial recovery of neuromuscular
transmission.
The observations just described do not specifically
demonstrate ACh release. Indeed, it is uncertain that the
sensitivity of FM1-43 uptake experiments is adequate to
detect the low levels of quantal release that may be able to
excite muscle fibres that have been functionally denervated
for some time. Using focal extracellular recording, capable
of detecting the effects of a single ACh quantum with
a spatial resolution of less than 10 μm (del Castillo &
Katz, 1954), we have found that in the mouse ETA muscle
(Bradley et al. 1989), although quantal release from the
newly formed synaptic contacts does occur, substantially
more quanta are released in the region of the original NMJ
at all stages of recovery.
The action of BoNT/A is known to result in changes in
the kinetics of quantal release at some synapses (Sakaba
et al. 2005). In addition, there is evidence that types
of voltage-gated calcium channel that are not normally
expressed at mammalian NMJs are active during recovery
from BoNT/A (Santafe et al. 2000). Although a number of
previous studies have noted an increase in the incidence
of ‘slow’ or ‘giant’ spontaneous mEPPs after exposure to
BoNT/A (Thesleff et al. 1983; Kim et al. 1984), little has
been reported about the properties of the evoked quantal
release that account for functional recovery of the NMJ. We
have therefore investigated changes in the temporal aspects
of evoked ACh release and found that evoked responses
are also significantly slower during the recovery from the
effects of BoNT/A.
Although multiple injections of BoNT/A are widely
used clinically to maintain muscle weakness, very little
is known about the ability of the NMJ to recover from
such repeated exposure. We have investigated the effects on
NMJs in the mouse ETA of up to three injections, given at
successive intervals of 3–4 months. Although there is sub-
stantial functional recovery even after three injections, this
recovery is significantly slower than after a single injection
and is associated with persisting structural abnormalities
of the terminal and preterminal motor axon.
Preliminary accounts of some of our observations have
been presented previously (Pang et al. 2002; Slater &
Rogozhin, 2006).
Methods
BoNT/A Administration
All studies were authorized by Project Licence PPL 60/3024
issued by the UK Home Office and approved by the
Newcastle University Ethics Committee. A total of 180
mice were used in the study.
All experiments were made on the epitrochleoanconeus
muscle (ETA), located superficially on the medial aspect of
the proximal forelimb (Bradley et al. 1989). To expose the
muscle to BoNT/A, the mice were anaesthetized (3% iso-
flurane) and a small incision (1 mm) made in the skin in
the right axilla. Ten microlitres of a solution containing
0.5 U of BoNT/A (BOTOX®, Allergan) in sterile saline
was injected under the skin over the ETA using a 10 μl
Hamilton syringe fitted with a 26 gauge needle. The skin
was closed with a single suture and 0.2 ml Buprenorphine
(1 : 100, subcutaneous) given to control pain. At the time
of the acute experiment, the mice were killed by cervical
dislocation.
Nerve–muscle preparations
In the adult mice used (female, ca 30 g) the ETA contains
about 400 muscle fibres, each about 9 mm long with a
mean diameter of about 35 μm. It is usually innervated by
five to seven motor neurons contained in a small branch
of the radial nerve. More than 90% of the muscle fibres are
‘fast’ as defined by myosin heavy chain immunolabelling.
The results from mice injected with BoNT/A
were compared to those from uninjected mice, from
mice injected with 10 μl of sterile saline (using the
same injection procedure outlined above), or from the
uninjected muscles contralateral to the experimental
muscles.
The experiments reported here were made on mice of
the strains CD1, MF1 or TO. No differences in the response
to BoNT/A between the strains was noted.
Electrophysiological studies
Animals were killed at various times after BoNT/A
injection by stunning and cervical dislocation. ETA
nerve–muscle preparations were then dissected out and
maintained at room temperature (20–23◦C) in Liley’s
solution containing (mm): 137.8 NaCl, 4 KCl, 2 CaCl2,
1 MgCl2, 1 KH2PO4, 12 NaHCO3, 11 glucose, gassed
with 95% O2–5% CO2 (Liley, 1956). The preparations
were pinned out in a recording chamber (Warner RC
27, Warner Instruments) with a volume of 2.5 ml, lined
with Sylgard (Dow Corning). A continuous flow of gassed
bathing fluid was maintained at 1 ml min−1 by a peri-
staltic pump. The muscle was viewed with a Leica DLFSA
fluorescence microscope (Leica Microsystems) fitted with
water immersion objectives (10–40×).
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The nerve was drawn up into a suction electrode
and routinely stimulated supramaximally with pulses of
0.1 ms duration. Intracellular recordings were made with
glass electrodes (ca 10 M resistance when filled with
3 m KCl), amplified by an Axoclamp 2B amplifier (Axon
Instruments/Molecular Devices), further amplified and
processed (filtered at 3 kHz) by a CyberAmp 380 (Axon
Instruments), and digitized at a sampling rate of 41.6 kHz
by a Digidata 1322A A/D converter (Axon Instruments)
before being displayed and saved using pCLAMP 9
software (Axon Instruments). Extracellular signals were
recorded with glass electrodes with an internal diameter
of 2 μm, filled with bathing fluid, and were amplified
by an AI402 head stage (Axon Instruments) feeding into
the CyberAmp (filtered at 10 kHz) and digitized as above.
Spontaneous events (mEPPs) were recorded in continuous
samples of 1–2 min duration.
The preparations were initially viewed in bright field
transmitted light with a 2.5× dry objective with a long
working distance. Compound muscle action potentials
(CMAPs) were recorded during stimulation of the nerve
at 1 Hz to provide an indication of the overall state of
functional innervation of the muscles before exposure
to labelling and blocking reagents (see below) (Fig. 1).
For this, an extracellular electrode (see above) was
positioned approximately 100 μm above the surface of the
muscle and moved parallel to the muscle fibres until a
response was observed starting with an abrupt negative
deflection, indicating proximity to the innervation zone.
The electrode position was then further optimized by
moving it laterally to the position where the largest
response was observed.
Once CMAPs had been recorded, the motor axon
terminals were labelled with the fluorescent dye
4-Di-2-ASP (Magrassi et al. 1987) (1 μm, 10 min;
Molecular Probes/Invitrogen, Paisley, UK) and viewed
with incident light using a fluorescein filter block (Leica
I3). Neutral density filters were used to reduce the intensity
of the incident light, typically 8-fold, to limit damage
to the preparation from phototoxicity. Images of the
labelled NMJs were recorded with a CoolSnapHQ cooled
CCD camera (Photometrics), controlled by MetaMorph
software (Molecular Devices). Exposures were usually of
1 s duration with the 40× objective.
Muscle action potentials were then blocked by exposing
the muscles to μ-conotoxin GIIIB (μCTX, 2 μm; Peptide
Institute, Osaka, Japan) for 15 min while the flow was
stopped (Plomp et al. 1992). The toxin solution was then
sucked out, the preparation returned to fresh bathing fluid
and the flow resumed. This procedure blocked muscle
contraction for 45–60 min, at which time the preparation
was re-exposed to the toxin.
After blocking contraction with μCTX, one or
two intracellular and two extracellular electrodes were
positioned approximately and the objective changed to
40× water immersion (2 mm working distance) to search
for NMJs located on the surface of the muscle. To
record synaptic potentials, the intracellular electrodes were
inserted into the muscle fibre 50–100 μm away from
the NMJ, to minimize damage to the nerve terminal.
When two intracellular electrodes were used, current was
passed through one to maintain the membrane potential
close to −75 mV. This ensured that measurements of the
amplitude and time course of synaptic events, which are
both influenced by the value of the membrane potential,
were all made at nearly the same membrane potential. EPPs
were routinely evoked by trains of 100 stimuli delivered at
a frequency of 1 Hz. In some cases, described in the text,
higher frequency trains were used. Spontaneous mEPPs
were recorded during continuous records of 1 or 2 min
duration. The EPPs and mEPPs recorded in this way are
referred to below as EPPin and mEPPin to distinguish them
from events recorded with extracellular electrodes.
To make focal recordings of synaptic events (del Castillo
& Katz, 1956) an extracellular electrode was positioned
close to a site of interest along the axon terminal or a sprout.
Gentle pressure was then applied, under visual control, to
bring the electrode into contact with the axon without
causing damage (signalled by an abrupt increase in mEPP
frequency).
The response to nerve stimulation recorded from
a single extracellular electrode positioned near the
innervation zone in a muscle blocked with μCTX is the
sum of a diffuse field potential from the summed EPPs
at a large number of NMJs, analogous to the CMAP, and
a much more localized response from the site of inter-
est, which we refer to here as EPPex. The field response
varied little with movements of the electrode of even
100 s of μm, but the local response was very sensitive
to movements of a few micrometres. To obtain the local
response without ‘contamination’ by the field response, a
second extracellular electrode was frequently positioned
5–10 μm away from the site of focal recording and the
signal from this reference electrode was subtracted from
the signal from the focal electrode (Katz & Miledi, 1965).
Successful placement of the focal electrode on the nerve
was indicated by the presence of a nerve action potential
in the average of a set of 25–100 responses (Angaut-Petit
et al. 1990).
In muscles that had been treated with BoNT/A, the
structure of the original NMJs was sometimes so altered
that they could not be identified with certainty. However,
fibres with clearly identifiable original NMJs were used
when possible, to allow reliable comparison of events
associated with the new sprouts with those arising in
the region of the original NMJs. In these muscles, most
recordings from sprouts were made within 50 μm of the
original NMJs.
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Analysis of electrophysiological data
All electrophysiological recordings were analysed with the
Clampfit package in pCLAMP 9 (Axon Instruments).
Spontaneous events were extracted using the ‘template
search’ facility.
Kinetics of synaptic events. EPPex latency was defined as
the time from the onset of the stimulus artefact to the time
when the potential reached 20% of its peak value. The rise
time and decay time of synaptic events was defined as the
time taken to go from 10 to 90%, or 90–10%, respectively,
of the peak amplitude.
Quantal content. The quantal content of the EPPin was
estimated from the ratio of EPPin amplitude to mEPPin
amplitude, after suitable correction of the signals for
membrane potential and nonlinear summation, assuming
a reversal potential of 0 mV (Martin, 1955; Slater et al.
1992). No additional adjustment was made for the effect
of membrane capacity on quantal content (McLachlan &
Martin, 1981) (equivalent to setting their f = 1).
Immunolabelling
Whole ETA muscles were incubated in
rhodamine–α-bungarotoxin (R-BgTx, 10−6 m; Molecular
Probes/Invitrogen) in Liley’s solution for 1 h and then
washed thoroughly. They were then fixed in 0.5–1%
paraformaldehyde in 0.1 m phosphate buffer for 30 min.
After washing in buffer, muscles were permeabilized
in alcohols (ethanol for 10 min followed by methanol
for 10 min, both at −20◦C) followed by incubation in
Triton X-100 (0.1%, 10 min, room temperature). They
were then incubated overnight at 4◦C in a mixture
of rabbit anti-neurofilament protein (NFP; AB1982,
Chemicon) and rabbit anti-synaptophysin (RB1461,
Neomarkers, Stratech), each at a dilution of 1/100, in
PBS containing 3% BSA (Sigma-Aldrich) and 0.1 m
lysine (Sigma-Aldrich). The next day, after washing in
PBS, they were incubated for 3 h at room temperature
in FITC–swine anti-rabbit (1/100) (DAKO) which had
been preincubated in half the volume of neat rat serum to
reduce non-specific binding. After washing overnight in
PBS, the muscles were mounted on slides in Vectashield
(Vector Laboratories).
Labelling of single teased muscle fibres
To assess the distribution of differentiated postsynaptic
sites, muscles were labelled with R-BgTx (10−6 m, 1 h) and
then fixed in 1% paraformaldehyde 1 h, 0.1 m phosphate
buffer. After fixation junctional regions, several milli-
metres long, of 30–50 individual fibres from each muscle
studied were dissected out and mounted in Vectashield for
subsequent analysis.
Microscopy
Image recording. Fixed preparations and teased fibres
were viewed with a Leica DMRA fluorescence microscope
(Leica Microsystems) using filter blocks N21 (TMRITC)
and L5 (FITC, selective). Images were captured with a
SPOT-II camera (Diagnostics Instruments) under control
by MetaMorph. When appropriate, Z-series were recorded
at a spacing of 1 or 2 μm using a 50× oil immersion
objective.
Image analysis. The area and number of regions of
postsynaptic differentiation were determined from teased
fibres. For each fibre, each of what appeared to be separate
regions of high R-BgTx labelling was outlined by hand. The
regions of high R-BgTx labelling at what appeared to be the
original endplate, i.e. to consist of a closely packed cluster
of highly intense spots, were also outlined. The areas of all
regions were calculated using MetaMorph.
Statistical analysis and data presentation
Averaged data are presented with the s.d. and relevant
sample size. The significance of differences between means
was determined using Student’s two-sided paired t test,
accounting for small samples where appropriate. The
relationship between number of BoNT/A injections and
rate of functional recovery, illustrated in Fig. 12, was
investigated using analysis of covariance (http://udel.
edu/∼mcdonanld/statancova.html).
Results
The initial aim of this study was to assess the contribution
of new synaptic contacts to the functional recovery of
mouse NMJs after exposure to BoNT/A. Before doing this,
it was necessary to establish the time course of functional
recovery and axonal sprout outgrowth as it occurs in the
mouse ETA muscle, since this has not been previously
described.
Time course of recovery from a single injection of
BoNT/A
Neuromuscular transmission. Nerve-evoked contraction
of the ETA was fully blocked within 1–2 days of BoNT/A
injection. The first visible signs of recovery occurred
2–3 weeks later, when weak contractions in response
to nerve stimulation could be seen. During the next
3–4 weeks the contractions grew in strength and became
hard to distinguish from normal by eye. During the
period of impaired transmission, many muscles displayed
spontaneous fibrillation, in a manner typical of denervated
muscles. This was most prominent 1–4 weeks after
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
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BoNT/A treatment. Occasionally spontaneous contra-
ctions were seen up to 4 months after BoNT/A treatment
but not after that time.
To provide a more quantitative measure of the overall
recovery of function, compound muscle action potentials
(CMAPs) were recorded (Fig. 1A). In control ETA muscles
these have a mean amplitude of 1.92 mV (s.d. 0.48 mV,
n = 10). They were completely abolished within 1–2 days
after BoNT/A injection (Fig. 1B). During recovery, CMAPs
were first detected at 2–3 weeks, and some were within
the normal range of amplitudes 8–10 weeks after BoNT/A
injection. Nonetheless, the CMAP amplitude was usually
less than normal even 10–12 weeks after BoNT/A.
Figure 1. Recovery of CMAP after exposure of mouse ETA to
BoNT/A
A, recordings of CMAPs at representative times during the course of
recovery. B, changes in amplitude of negative peak of CMAP as a
function of time after exposure to BoNT/A. Each point represents a
single muscle. Open symbol on ordinate shows mean value for 10
control muscles ± S.D.
To assess the changes in quantal release of ACh from the
whole motor nerve terminal we used intracellular electro-
des to record EPPins and mEPPins. From their amplitudes
we calculated the quantal content (see Methods). These
values are shown, as a function of time after BoNT/A
injection, in Fig. 2. At NMJs in normal ETA muscles,
the quantal content in our conditions was 57.9 (s.d. 26.8,
n = 10). The quantal content fell to < 0.1 within 1–2 days
after BoNT/A. The first NMJs where the QC had increased
to > 1 were seen 12 days after injecting BoNT/A. By
6–7 weeks after BoNT/A the QC was about 60% (33.2,
s.d. 13.1, n = 3) of normal and after 10–14 weeks was
indistinguishable from normal (61.6, s.d. 15.2, n = 5).
The mean EPPin amplitude was significantly correlated
with the CMAP amplitude in the same muscle throughout
the recovery period (r = 0.92, n = 53, P < 0.001). This
implies that the experimental treatments used to record
EPPs (μCTX, 4-Di-2-ASP) did not have a disproportionate
effect on, for example, quantal release early in recovery.
Mice of several strains were used in the course of this
project (see Methods). No differences between the strains
were observed in either the timing or extent of recovery.
Nerve sprouting and AChR accumulation. After exposure
to a blocking dose of BoNT/A, sprouts grow out from the
motor axon terminals and appear to establish new synaptic
contacts with nearby muscle fibres (Duchen, 1970; Juzans
et al. 1996a; de Paiva et al. 1999; Santafe et al. 2000).
We investigated the process of axonal sprout formation
and differentiation to see how it was related in time to
the recovery of quantal release in the ETA. Muscles were
labelled with antibodies to NFP and synaptophysin to
reveal the nerves and their terminals and with R-BgTx to
visualize the distribution of postsynaptic AChRs.
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Figure 2. Recovery of evoked quantal release after exposure of
mouse ETA to BoNT/A
Quantal content of the EPPin, calculated from mean amplitudes of
mEPPins and EPPins (see Methods). Each point represents the mean of
values from approximately 10 NMJs in a single muscle. Open symbol
on ordinate shows mean value for 10 control muscles ± S.D.
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Axonal sprouts could be seen extending from the
motor axon terminals within a week or less of BoNT/A
injection (Fig. 3A, ‘1–2 weeks’). Over the next few weeks,
these sprouts grew further, primarily along the muscle
fibres. From about 2 weeks after BoNT/A injection, lateral
branches began to emerge from the main longitudinal
sprouts and then gradually increased in length. From an
early stage, many of the growing ends of the sprouts ended
in roughly circular varicosities, typically about 3 μm in
diameter.
Figure 3. Axonal sprouting induced by exposure of mouse ETA
muscle to BoNT/A
A, images of terminal motor innervation at representative times during
recovery. Nerves labelled with antibodies to neurofilament protein and
synaptophysin (green), AChRs in muscle labelled with R-BgTx (red).
The appearances illustrated in each panel are typical of those seen at
the indicated times after injection of BoNT/A. B, time course of events
in the response of NMJs to exposure to BoNT/A, expressed as the
fraction of NMJs (%) having the features shown. Sprouts form within
the first week or so and AChR clusters appear a few days later. The
increase in quantal release is indicated by curves showing the fraction
of NMJs with QC > 5, representing an unambiguous increase from the
blocked level, and of NMJs with QC > 25, a value likely to cause
muscle fibre excitation and contraction. Each point represents the
mean of values from 1–5 muscles.
Clusters of AChRs, adjacent to the growing sprouts,
were apparent from about 2 weeks of BoNT/A injection
(Fig. 3A, ‘2–3 weeks’). Initially, these appeared as faint,
poorly defined clusters lying along the sprouts. As the
lateral branches formed, most of the AChR clusters took on
a circular, spot-like form, coincident with the varicosities,
and grew brighter and more clearly defined (Fig. 3A,
‘3–4 weeks’). At times greater than 4 weeks after BoNT/A
injection many of the AChR clusters had bright rims,
similar to those seen at normal NMJs, suggesting the pre-
sence of a concave depression in the surface of the muscle
fibre at the new synaptic sites (Fig. 3A, ‘> 4 weeks’). At no
time in the formation and maturation of new contacts were
AChR clusters seen that were not close to axon sprouts.
We quantified the incidence of sprouts and AChR
clusters after BoNT/A intoxication in order to relate their
appearance to the onset of evoked quantal release (Fig. 3B).
At a population level, the AChR clusters form about 5 days
after the formation of sprouts. A clear increase in quantal
content, represented by the fraction of NMJs where the
quantal content has increased to > 5 (normal value 58), is
present at 50% of NMJs by about a week after AChR clusters
form. To trigger a muscle action potential and contraction
probably requires the release of about 25 quanta (based
on data from rat soleus muscles; Wood & Slater, 1997).
As shown in Fig. 3B, this level of release occurs at 50% of
NMJs by about 40 days after BoNT/A.
In summary, our observations of the ETA confirm earlier
observations (de Paiva et al. 1999) that after an injection
of BoNT/A, well formed axonal sprouts whose terminals
are associated with AChR clusters are already present for
several days before quantal release of ACh becomes readily
detectable. However, the entire recovery process occurs
more rapidly in ETA than in the mouse soleus, extensor
digitorum longus or levator auris (LAL) (Duchen, 1970;
Tonge, 1974; Santafe et al. 2000). We have confirmed the
slower recovery in soleus (L. Gurney, K. K. Pang & C. R.
Slater, unpublished observations).
How much do new synaptic contacts contribute to
functional recovery?
To estimate the contribution of new synaptic sites to
the initial recovery after exposure to BoNT/A, we first
located individual new synaptic sites and then estimated
the intensity of release from them. We then determined the
extent and number of such new synaptic contacts. Finally
we used these data to estimate the summed contribution
of release from all the new sites on a muscle fibre to the
total quantal content.
Location of release sites. The spatial resolution of intra-
cellular recording does not allow quanta released from
new synaptic sites to be easily distinguished from those
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
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released from the site of the original NMJ. To study release
from new sprouts, we therefore used focal extracellular
recording (del Castillo & Katz, 1954), which allows the
sites of synaptic current generation to be defined with a
resolution of 5–10 μm.
The nerve–muscle preparations were routinely labelled
with the mitochondrial dye 4-Di-2-ASP to allow the nerve
and its sprouts to be visualized during electrophysiological
recording (Magrassi et al. 1987). Normal nerve terminals
labelled with this dye generally appear as a compact cluster
of discrete varicosities, each typically 2–3 μm in diameter
(Fig. 4). Extracellular electrodes placed near such labelled
spots frequently record both spontaneous and evoked
quantal events which we refer to as EPPex. Comparison of
records from two electrodes placed at different spots at the
same normal NMJ confirms that this mode of recording
can differentiate between quanta released from sites less
than 10 μm apart (Fig. 4).
Axonal sprouts induced by BoNT/A are also labelled
by 4-Di-2-ASP (Fig. 5A) (cf. de Paiva et al. 1999). Like
normal nerve terminals they appear as a number of discrete
varicosities, but ones that lie outside a region bounded by
a smoothly contoured line enclosing the original nerve
terminal. Such a line is shown in Fig. 5A. In the later
stages of recovery from BoNT/A, recordings of evoked
and spontaneous quantal release could almost always be
obtained when the electrode was placed over such spots
(see below), confirming that they correspond to discrete
sites of quantal release along the sprouts. Movements of
the electrode of only a few micrometres away from these
spots resulted in a great reduction in the amplitude of the
spontaneous events. At the same time, the amplitude of the
evoked responses was reduced to a level that was relatively
independent of position. This ‘field’ signal, analogous to
the CMAP, represents the effects of the summed end-
plate currents from many NMJs. We often placed a second
extracellular electrode near the first to record this ‘field’
EPP so that it could be subtracted to reveal the ‘specific’,
position-dependent responses (cf. Fig. 5B) (Katz & Miledi,
1965).
During the initial recovery phase, 2–6 weeks after
BoNT/A, synaptic events could be recorded with an
extracellular electrode both at the sites of the original NMJs
and at varicosities on sprouts (Fig. 5B). In this figure, the
six to eight responses shown were selected from series of
100 trials to illustrate the range of amplitudes, and do not
necessarily represent the average responses (see below). In
general, synaptic activity was always easier to record from
the original NMJs than from the sprouts. However, this
effect is difficult to quantify because at many spots it was
necessary to reposition the recording electrode repeatedly
before synaptic events were detected. Thus the absence
of detectable events at any particular recording site was
not always a good indication of an absence of quantal
release. On the other hand, even a single recorded event,
as illustrated in Fig. 5B ‘New’, is clear evidence that the
electrode is adequately placed to record synaptic events.
An important additional indication that the recording
electrode was placed over a sprout was the ability to
record an extracellular nerve action potential (Brigant &
Mallart, 1982; Mallart & Brigant, 1982; Angaut-Petit et al.
1990). The detection of these signals was improved if the
electrode was pressed against the sprout. However, this
risked causing mechanical damage. We therefore generally
looked for the nerve action potentials in averages of
25–100 traces. Only when both 4-Di-2-ASP labelling and
an extracellular nerve action potential were present was the
absence of detectable synaptic events taken as a significant
negative finding.
Assessment of release. Early in recovery only occasional
stimuli evoked detectable responses at any extracellular
recording site (Fig. 5B). For example, at the NMJ illustrated
Figure 4. Spatial discrimination of focal extracellular recording
A, a fluorescence image of an ETA NMJ after labelling with 4-Di-2-ASP
merged with a bright field image showing muscle fibre and electrodes.
Two extracellular electrodes (‘Ex 1’ and ‘Ex 2’) are positioned on
different parts of the nerve terminal, 8.9 μm apart. The position of the
two intracellular electrodes (‘V’ and ‘I’), both slightly out of focus in
this image, are indicated by arrows. Electrode ‘V’ is used to record
membrane potential and electrode ‘I’ is used to pass current to
maintain membrane potential near −75 mV. B, the bottom trace
shows mEPPs recorded with the intracellular electrode (‘V’) and the
other two traces show recordings by the two extracellular electrodes.
The difference in the recordings from these two electrodes gives an
indication of the spatial resolution of this approach.
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in Fig. 5, 21 days after BoNT/A, responses from the original
NMJ were seen in 28/100 trials and in only 1/100 trials at
the ‘new’ site. In contrast, EPPins were recorded in 82/100
and 84/100 in these two series of trials.
The very low frequency of spontaneous mEPPexs
observed made it impractical to estimate directly the mean
number of quanta released by a single nerve impulse from
new synaptic spots. Instead, we made the assumption
that during the early stages of recovery, as in many other
situations where quantal content is low, the release process
obeyed Poisson statistics (Katz, 1969). Analysis of the
distribution of amplitudes of EPPexs suggested that this was
a valid assumption. For example, at the NMJ illustrated in
Fig. 5, the series of 100 trials recorded from the ‘original’
site included 72 ‘failures’, i.e. stimuli that failed to evoke
a detectable response, 24 responses whose amplitude was
intermediate in amplitude (mean 0.15 ± 0.024 mV) and
four responses whose amplitude was clearly greater (mean
0.27 ± 0.030 mV). The Poisson distribution predicts that
for a failure rate of 72%, 24% of the responses should
consist of 1 quantum and 4% of 2. In this case, the observed
distribution of EPPex amplitudes agreed well with that
predicted by the Poisson distribution for a mean quantal
content of 0.33.
We therefore used the fraction of response ‘failures’ to
estimate the mean number of quanta released in the pickup
area of the electrode. We defined this value as the ‘local’
quantal content (QClocal), i.e. the mean number of quanta
detected by the extracellular electrode at a given recording
site in response to a single stimulus. An inherent limitation
Figure 5. Localization of evoked quantal
release
A, image of nerve terminal, labelled with
4-Di-2-ASP, from mouse ETA 21 days after
exposure to BoNT/A. Two extracellular recording
positions are indicated, one over part of the
original terminal and one over a newly formed
synaptic spot about 10 μm away. The limits of
what is considered the original terminal are
shown by a continuous white line. B, recordings
from the two sites depicted in A. For each site
the upper traces are from the extracellular
electrode, with downward deflections indicating
evoked synaptic currents. The lower traces are
from an intracellular electrode. Six pairs of
traces, which were selected from a series of 100
to show the range of values observed, are
shown for each site. One pair from each site has
been shown in grey. At each site most stimuli
failed to evoke any localized extracellular
response even though an EPPin was present. At
the ‘new’ site the trace in grey was the only
clear response seen in 100 trials. Further details
in text.
of this method for estimating QClocal is that it can only be
used when the fraction of failures is greater than about 5%.
This was generally the case up to 6–8 weeks after exposure
to BoNT/A.
Comparison of the QClocal at original and new synaptic
sites shows that at the earliest stages of functional recovery,
2–3 weeks after exposure to BoNT/A, more quanta were
released by a single nerve action potential at recording
sites at the original NMJ than at the new synaptic spots
(Fig. 6). This situation was maintained for at least
2 months, by which time overall recovery of quantal
release was more than 50% complete. During the period
2–12 weeks after exposure to BoNT/A, the mean QClocal at
‘new’ synaptic spots was 17% (s.d. 19%, n = 10 muscles)
of that from sites in the original junctional region.
Extent of new synaptic contacts. To estimate the summed
contribution of quantal release from new synaptic contacts
to the overall quantal content at recovering NMJs, we
needed to establish the spatial extent and number of the
new synaptic regions. To do this we defined and measured
all the regions of high AChR density, marked by labelling
with R-BgTx, on individual ETA muscle fibres teased
from muscles at various times after exposure to BoNT/A.
Examples of muscle fibres in different stages of recovery are
shown in Fig. 7A. In the example from 14 days, when most
NMJs have many axonal sprouts, no new AChR clusters
have formed. In the example from 17 days, faint, poorly
defined clusters can be seen up to 75 μm from the original
NMJ. By 24 days, the AChR clusters are much brighter
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and are more clearly defined. We traced around each of
these AChR clusters and then measured its area. Most
individual AChR ‘spots’ are 3–5 μm in diameter. Often,
a number of spots were close enough to each other so that
their boundaries were hard to resolve. In these cases, we
traced around a cluster of contiguous spots. We refer below
to a ‘region’ of high AChR density as a spot or a collection
of spots so close together that they were included in the
same measuring profile.
The total area of new synaptic contacts on a given fibre
was generally substantially less than that of the original
NMJ (Fig. 7B). During the first 3 weeks after BoNT/A
injection, the total area of new contacts per muscle fibre
increased to about 70 μm2 and then remained at that level
(mean 67.5 μm2, s.d. 33.6, n = 15 muscles, for the period
3–7 weeks). In contrast, original NMJs have an area of
218 μm2 (s.d. 35.0, n = 15). Thus, during most of the
recovery phase, the area of the new contacts was about
30% of that of the originals, or about 25% of the total
area of high AChR density per muscle fibre. The mean
number of contiguous regions of AChR labelling during
the period 3–7 weeks after BoNT/A was 4.95 (s.d. 2.05,
n = 8 muscles) per muscle fibre (Fig. 7C), giving an average
area of such regions as 13.6 μm2. This analysis shows that
in the majority of muscle fibres, the area of new synaptic
contacts remained a relatively small fraction of the total
synaptic area.
Contribution of new synaptic contacts to functional
recovery. We estimated the quantal content from new
contacts by assuming that our extracellular recordings
detected quanta from a single region of new synaptic
contact. This seemed justified because the average area
of these regions (13.6 μm2) is well within the pickup area
of the extracellular electrodes (100–300 μm2), and there
was generally a distance of at least 10 μm between these
regions (cf. Fig. 7A; 17 and 24 days). On this basis, the total
quantal content is given by the product of the number
of regions per muscle fibre and the local quantal content.
When new AChR clusters were closer together than 10 μm,
this procedure would tend to overestimate release from
new spots. The resulting values are shown in Fig. 8, in
which data have been pooled into bins 5 days wide.
From the earliest time when recovery of quantal release
can be reliably detected, the total number of quanta
released from new synaptic contacts is substantially less
than from the sites of the original NMJs. On average,
throughout the first 6 weeks after BoNT/A, release from
new contacts was 17% of that from original NMJs (s.d.
19%, n = 10).
Temporal features of evoked synaptic events during
recovery
In the course of our studies it became clear that there
were significant changes in both the latency and time
course of the evoked synaptic responses at NMJs during
the process of recovery from BoNT/A. Since it is known
that cleavage of SNAP-25 by BoNT/A influences the
dynamics of quantal release at other synapses (Sakaba
et al. 2005), we attempted to define these changes in more
detail.
Latency and synaptic delay of evoked synaptic events
during recovery from BoNT/A. In a previous study, made
on the LAL muscle of mice, it was found that the
latency of EPPs increased during recovery from BoNT/A
(Santafe et al. 2000). The latency of the EPP has two
components: the conduction time in the nerve and the
synaptic delay between the arrival of the nerve impulse and
detectable quantal release. To distinguish between these
factors as determinants of the increased latency, we studied
EPPexs. During the first 30 days after BoNT/A, the average
latency from stimulus to onset of EPPex was nearly twice
as long as normal (control, 1.1 ± 0.13 ms, n = 5 versus
BoNT/A, 1.9 ± 0.33 ms, n = 23, P < 0.0001) (Fig. 9A
and B).
The conduction velocity along sprouts evoked by
BoNT/A in the mouse LAL has been reported as 0.24 m s−1
(Angaut-Petit et al. 1990), a value not far from that
originally measured at normal frog motor nerve terminals
(0.3 m s−1) (Katz & Miledi, 1965). In the ETA, in muscles
up to 36 days after BoNT/A, we observed a value of
0.17 m s−1 (s.d. 0.08, n = 8). Few of the sprouts we
studied were more than 100 μm long (see Santafe et al.
2000). For a sprout of that length, assuming a conduction
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Figure 6. Comparison of the intensity of evoked quantal release
at new and original synaptic sites during recovery of mouse ETA
NMJs from exposure to BoNT/A
The local quantal contents (QClocal) of the extracellular responses to
nerve stimulation, calculated from the fraction of ‘failures’ using the
Poisson distribution (see text for further details), are shown as a
function of time after exposure to BoNT/A. Each point represents the
mean of values from 1 to 27 (mean 18) fibres in 2–8 (mean 5) muscles
at times < 40 days, and 1–2 muscles for times > 40 days, pooled into
5-day intervals after exposure to BoNT/A.
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Figure 7. Extent of AChR clusters at new synaptic spots that
form during recovery of mouse ETA muscles after exposure to
BoNT/A
A, images of AChRs, labelled with R-BgTx, at representative times
during recovery. Arrows point to new synaptic spots. At 17 days these
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Figure 8. Estimated contribution of quantal release from new
synaptic spots to neuromuscular transmission during recovery
from exposure of mouse ETA to BoNT/A
Open symbols, total quantal content recorded with an intracellular
electrode; filled symbols, estimated quantal release from all new
synaptic spots on individual muscle fibres (see text). Points represent
mean values from 1 to 8 (mean 3.4) muscles, pooled into 5-day
intervals after exposure to BoNT/A. Typically 2–3 fibres were studied in
detail in each muscle. Note that at all times, the estimated
contribution from new synaptic sites is a small fraction of the total.
velocity of 0.2 m s−1, the conduction time along the entire
sprout would be 0.5 ms. While it is thus likely that the
conduction time accounts for some of the increased latency
at new synaptic sites on the longest sprouts, we observed
no significant difference between the observed average
latencies at sites on sprouts (1.9 ± 0.48 ms, n = 5) and at
the site of the original NMJ (1.9 ± 0.26 ms, n = 18) during
the period up to 30 days after exposure to BoNT/A.
In contrast, we found clear evidence for an increase in
the second component of EPP latency, the synaptic delay.
We defined this as the time from the negative peak of the
nerve action potential to the foot of the EPPex (Fig. 9C). At
those NMJs where both a clear nerve action potential and
EPPex were recorded, the synaptic delay increased from a
normal value of 0.32 ± 0.034 ms (n = 8) to 0.73 ± 0.16 ms
(n = 26 NMJs studied up to 30 days after exposure to
BoNT/A, P < 0.0001). There was no significant difference
between the delays observed at new and original sites
(0.70 ± 0.14 ms, n = 6 versus 0.74 ± 0.17 ms, n = 20).
Thus, during recovery from BoNT/A, the events coupling
are fainter and less well-defined than at 24 days. B, total area, per
muscle fibre, of AChR clusters at original NMJs and at new synaptic
sites as a function of time after exposure to BoNT/A. At all times the
area of new sites is substantially less than that of the original NMJs. C,
mean number of separate regions of high AChR density on individual
muscle fibres as a function of time after exposure to BoNT/A. Each
point represents the mean of data from 1 to 4 muscles pooled into
5-day intervals after exposure to BoNT/A.
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nerve terminal depolarization to quantal release occur
more slowly than normal.
Kinetics of synaptic potentials during recovery. During
the early stages of recovery of transmission, evoked
synaptic potentials with an unusually slow time course
were sometimes seen (Fig. 10). Some of these recalled
the ‘giant’ or ‘slow’ spontaneous miniature potentials
previously described by others (Thesleff & Molgo, 1983;
Thesleff et al. 1983; Kim et al. 1984). In those earlier
studies, changes in the time course of evoked events were
not reported.
A systematic study of the time course of individual
EPPins showed that during the initial recovery process,
both the rise and decay times were substantially
longer than normal (Fig. 10A and B). In the period
12–22 days after exposure to BoNT/A, the rise time
of EPPins was 1.61 ± 0.20 ms (control 0.53 ± 0.015 ms,
P = 0.0014) and the decay time was 15.07 ± 1.87 ms
(control 4.52 ± 1.19 ms, P = 0.0002). The mean values
for individual muscles were highly significantly correlated
(P < 0.001). The period of prolonged kinetics lasted about
4 weeks, and was followed by a return to normal values
about 6 weeks after exposure to BoNT/A (Fig. 10C and D).
Thus, the average kinetic properties of the EPPins returned
to near normal values when the mean quantal content was
about 25, still less than half its normal value. This suggests
that the changes in EPPin time course at individual synaptic
sites are short-lived.
Of particular interest were a small number of fibres
where more than one population of EPPins, differing in
time course were present (Fig. 10E–H). Figure 10E shows
most of the 71 events evoked during a series of 100 trials
from one of these fibres. Of the 100 responses, 29 were
‘failures’, indicating that the quantal content of the EPPin
was 1.24. Of the events that were evoked, 52 were ‘pure
fast’ (e.g. Fig. 10F), 7 were ‘pure slow’ (Fig. 10H) and
12 were ‘mixed’ (Fig. 10G), apparently the sum of a fast
and a slow response. Thus 64 responses included a fast
response and 19 a slow response. If the responses of these
two classes arose independently, the probability that both
a fast and a slow response would appear in the same
trial is 0.64 × 0.19 = 0.12. This predicts that 12 responses
should be mixed, whereas 11 were observed. The results
of this analysis thus support the view that the two classes
of response at this and several other similar NMJs were
evoked independently. Unfortunately, these fibres were too
rare to allow detailed analysis of the sites of origin of the
two different classes of evoked response.
Response to repetitive stimulation. The results described
so far relate to NMJs stimulated at 1 Hz. As a further
test of the recovery of quantal release, in conditions more
related to normal functioning, we studied the response
Figure 9. Temporal changes in onset of evoked responses
during recovery from BoNT/A
A, records showing averaged EPPexs recorded from a control NMJ,
from new synaptic contacts 16 days after exposure to BoNT/A and
from the site of an original NMJs 21 days after exposure to BoNT/A. B,
changes in EPPex latency (time from stimulus artefact to 20% of peak
amplitude of EPP). C, changes in synaptic delay (time from negative
peak of nerve action potential to 20% of peak amplitude of EPPex).
Note that the time course with which both latency and synaptic delay
approach normal values is similar at the new contacts and at the
original NMJs. Each data point represents averaged data from one
recording site.
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Figure 10. Changes in kinetic properties of EPPins during recovery from exposure of mouse ETA muscles
to BoNT/A
All recordings show EPPins selected from trains of 100 stimuli (1 Hz). A, typical EPPs (14 superimposed) from
uninjected muscles. Note minimal variation of amplitude or time course. B, superimposed EPPins from ETA injected
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to repetitive stimulation in some muscles 4 months
after exposure to BoNT/A. Over the frequency range of
1–100 Hz, the properties of release at NMJs exposed to a
single injection at BoNT/A were qualitatively similar to
normal (Fig. 11). At frequencies below 50 Hz there was a
depression of release during a train of 100 stimuli. This
included both a rapid phase consisting of the first 20 or so
responses followed by a much slower phase. At 50 and
100 Hz, these two phases of depression were preceded
by a brief phase of potentiation. This resulted in EPPins
amplitudes about 1.2 times the initial value at both treated
and control NMJs.
Recovery from multiple injections of BoNT/A
Recovery of neuromuscular transmission. It is clear from
clinical experience that some degree of functional recovery
is possible even after multiple injections of BoNT/A.
However, we are unaware of any reports of systematic
studies of functional recovery of quantal release after more
than one exposure to BoNT/A. We therefore investigated
the recovery of quantal content in the ETA muscles after
two and three injections, given at intervals of roughly
3–4 months (Fig. 12). In each case, the standard BoNT/A
injection initially caused a rapid and profound block of
quantal release.
Quantal release recovered significantly after both two
and three injections, but more slowly than after a single
injection. The slope of the regression line for recovery
after a single injection was 0.89 quantal units day−1. The
slopes of the regression lines for recovery after two or three
injections were not significantly different from each other.
When these data were pooled, the slope of the regression
for recovery after more than one injection was one-third
of that for recovery after a single injection (0.30 quantal
units day−1). On the basis of these regression lines, the
time for the quantal content to reach 50% of its normal
value (57.9) was 43 days for one injection, 74 for two and
105 for three.
The statistical strength of these conclusions was tested
using ANCOVA. The outcomes of this analysis are: (1)
the regressions of the three groups (1, 2 and 3 injections)
are not homogeneous (P = 0.018), (2) the regressions of
the data for two and three injections are not significantly
21 days previously. Note great variation of both amplitude and time course, and much smaller amplitude than
in control. C and D, changes in mean value of EPPin rise time (C, ‘RT’) and decay time (D, ‘DT’) during recovery
from BoNT/A. The total quantal content is shown in each graph for comparison. Note that the kinetic properties
of the EPPin return to normal values when the total quantal content has only reached approximately one-third of
its normal value. E, variable time courses of EPPins recorded from the same muscle fibre, 15 days after exposure to
BoNT/A. EPPins of two quite distinct time courses could be recorded from this fibre. Examples of these are shown
in F (fast EPPins), G (mixed time-course EPPins) and H (slow EPPins). A single response showing both fast and slow
components is highlighted in G.
different, (3) the regression of the data for one injection is
significantly different from that for either two (P < 0.0001)
or three (P << 0.0001) injections, and (4) the regression
of the data for one injection is significantly different from
that for the pooled data for two and three injections
(P << 0.0001). It is thus clear that in these experiments,
recovery of evoked quantal release after an injection of
BoNT/A was significantly slower in those mice that had
received one or two previous injections.
Structural abnormalities persist after multiple BoNT/A
injections. Although no systematic studies have been
made, available evidence indicates that structural
abnormalities of motor innervation persist in humans
for years after the last of a series of BoNT/A injections
(Alderson et al. 1991). We were therefore interested to
see whether NMJs in the mouse ETA whose function
had recovered after two or three BoNT/A injections
showed similarly persistent structural abnormalities. In
spite of the clear functional recovery, the abnormalities
of the anatomical features of motor innervation were still
present months after a second or, as illustrated in Fig. 13,
a third injection.
At low magnifications, it was clear that the central band
of innervation was much wider in injected muscles than in
uninjected contralateral controls (Fig. 13A and C). In the
examples illustrated (uninjected control and 124 days after
BoNT/A) the innervation band is more than twice as wide
as normal, and this was typical of the muscles we observed.
We did not attempt to quantify this increase in detail, or to
establish whether the width increased progressively with
the number of injections.
At higher magnification, it was clear that the individual
NMJs were also often very abnormal. Some examples
from muscles at 124 days after a third injection of
BoNT/A are shown in Fig. 13D–G. These show both
persisting individual sprouts (Fig. 13D) and multiple
lateral sprouts (Fig. 13F and G). At longer times after the
final injection of BoNT/A (223 days), a number of very
abnormal NMJs persisted (Fig. 13H–K). These were often
associated with lateral branches of long myelinated axons
coursing along the muscle fibres (Fig. 13I). Although
NMJs from uninjected contralateral muscles were often
rather complex (Fig. 13B), probably a result of the
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Figure 11. Response to repetitive stimulation of uninjected
control NMJs and NMJs 4 months after recovery from BoNT/A
In each case trains of 100 stimuli were given at frequencies from 1 to
100 Hz and the peak amplitudes of the resulting EPPins are plotted.
For both control (A) and recovered (B and C) NMJs, stimulation at 50
and 100 Hz caused initial facilitation followed by substantial
depression. At 1–20 Hz, there was depression but no facilitation. The
graphs show averaged pooled data from 75 NMJs from 5 uninjected
control mice (A), from 45 NMJs from 3 mice 4 months after a single
injection (B), and from 45 NMJs from 3 mice after a 2nd injection,
given 4 months after the first (C).
advanced age (476 days) (Barker & Ip, 1966; Tuffery, 1971;
Cardasis & LaFontaine, 1987), they only rarely had sprouts.
In summary, it is clear that although substantial recovery
of quantal release occurs in ETA muscles after two or three
injection of BoNT/A, striking structural abnormalities of
the motor axons and NMJs may persist for many months.
Discussion
Summary of main results
An important finding of our study of the mouse ETA is
that the region of the original NMJ plays a much greater
role in the initial recovery from the blocking effects of
BoNT/A than previously thought. In fact, our estimates
of quantal release from new synaptic contacts suggest that
they play a relatively minor role in functional recovery. A
second important finding is that after several exposures
to BoNT/A, while neuromuscular transmission can be
restored to near normal levels, it does so more slowly than
after a single exposure and is accompanied by profound
abnormalities in the structure of the intramuscular nerve
and the NMJs. These findings raise some concerns about
the cumulative effects of repeated exposure to BoNT/A
in a therapeutic or cosmetic context. At the same time,
they attest to the remarkable adaptive plasticity of the
mammalian NMJ.
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Figure 12. Recovery of quantal content at mouse ETA NMJs
after one, two or three injections of BoNT/A
Injections were given at intervals of 3–4 months. Time is shown after
the final injection. Note that recovery after 2 and 3 injections is slower
than after a single injection. Each point indicates averaged values of
pooled data from a number of fibres, typically 10, in one mouse.
Regression lines have been drawn through the data for each number
of injections: dotted, 1 injection; dashed, 2 injections; continuous, 3
injections. Statistical analysis is described in the text.
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Initial recovery
Timing of recovery. The time course of recovery of
quantal release after administration of BoNT/A is similar
Figure 13. Abnormal structural aspects of motor innervation after three injections of BoNT/A
Nerves (green) immunolabelled with anti-NFP and anti-synaptophysin, AChR (red) labelled with R-BgTx). A and C,
low magnification (scale bar in A also applies to C) views of normal (saline injected) ETA and an ETA from a mouse
of approximately the same age (476 days) which had received 3 injections of BoNT/A at approximately 3-monthly
intervals. The band containing NMJs is about twice as wide as normal indicating persisting abnormal distribution
of NMJs. B and D–G, higher magnification views (scale bar in B applies to all 5 panels). B is from an uninjected
muscle showing NMJ structure typical of mice of this age, consisting of a compact cluster of spot-like regions.
D–G show a selection of NMJs from injected muscles, 124 days after the 3rd injection. While the NMJ in E has a
structure within the normal range, the others show synaptic spots arising from ultraterminal sprouts (D) or short
lateral axonal branches (F and G) that are very rarely seen in normal muscles. H–K, ETA muscle 223 days after 3rd
injection of BoNT/A. The lower magnification views (H and I, same magnification) show axons coursing along the
muscle fibres while the higher magnification views (J and K, same magnification) show abnormal distributions of
AChR clusters.
in the ETA to that described for sternomastoid (de Paiva
et al. 1999) but is somewhat faster than that reported for
other mouse muscles (soleus, EDL, LAL) where quantal
content reached 50% of its normal value in 10–14 weeks
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(Tonge, 1974; Santafe et al. 2000). In making these
comparisons, it is important to bear in mind that different
preparations of BoNT/A were used, and possibly different
effective doses, and that different methods were used to
estimate quantal content. In spite of these differences, the
time required for all these mouse muscles to recover after
BoNT/A is roughly similar to the duration of effectiveness
of a single injection in man. It should be noted, however,
that because of the high safety factor for neuromuscular
transmission (Wood & Slater, 2001), patients may sense
significant functional recovery when transmission is still
substantially depressed. What of course differs between
mice and men is the fraction of the lifespan required for
recovery.
Several studies have noticed the ‘weaker’ sprouting
response evoked by BoNT/A in functionally fast muscles
(Duchen, 1970; Brown et al. 1980; Caroni et al. 1997;
Frey et al. 2000). It is reasonable to suppose that that the
pattern of short, high frequency bursts characteristic of
fast motor units (Hennig & Lomo, 1985), which is known
to be particularly effective in suppressing many effects
of muscle inactivity (Windisch et al. 1998), might also
suppress axonal sprouting and thus hinder recovery from
BoNT/A (Brown et al. 1980). However, it is clear from
both our observations of the ETA and previous studies
of the LAL (Juzans et al. 1996a) that rapid and extensive
sprouting can occur in an almost exclusively fast muscle,
and that functional recovery can also be relatively fast. As
discussed below, one possible explanation for this may be
that fast muscles tend to make new sprouts within the area
of the original NMJ.
Contribution of new synaptic contacts to recovery. Our
conclusions concerning the role of new synaptic contacts
to functional recovery from BoNT/A differ substantially
from those of the only previous study to investigate this
point (de Paiva et al. 1999; Meunier et al. 2003). Because
the conclusions of that study have been cited in a number of
subsequent articles (Meunier et al. 2002; Foran et al. 2003;
Dolly & Aoki, 2006; Osborne et al. 2007), it is important
to consider the possible origins of these differences.
de Paiva et al. (1999) used FM1-43 uptake to assess
nerve terminal function. In many situations, a good
correspondence between the intensity of FM1-43 labelling
and quantal release has been demonstrated (Cochilla et al.
1999). However, in the present situation, this method has
certain limitations. One is its inherent sensitivity. During
the early stages of recovery after BoNT/A, the intensity
of quantal release we observed at the sites of the original
NMJs is only a few per cent of normal. While electro-
physiological recording is capable of detecting the effects
of individual quanta, the fluorescence signals associated
with such low levels of release would be difficult to detect.
Further, it is important to note that the lowest levels of
FM1-43 labelling of the original terminals documented by
de Paiva et al. remained at 10–25% of the normal value
(see their Fig. 1h; de Paiva et al. 1999). However in studies,
including the present one, where quantal release has been
measured directly, it has initially fallen to less than 1%
of normal. This suggests that the intensity of FM1-43
fluorescence may not accurately reflect the low levels of
quantal release that follow BoNT/A intoxication.
An important further assumption made by de Paiva et al.
1999 is that the FM1-43 signal from the entire length of
the sprouts reflects physiologically significant transmitter
release. Only transmitter quanta released within a few
micrometres of AChR clusters can have any impact on
membrane excitation. However, it is clear from de Paiva
et al. and from this study that AChR clusters occupy only
a small fraction of the total length of the sprouts (cf. Figs 3
and 13). Thus, while membrane cycling may occur all along
the sprouts as they grow and extend lateral branches, much
of this may not be relevant for quantal release of ACh. Our
electrophysiological approach, while not measuring ACh
release directly, does indicate ‘effective’ release, i.e. that
which leads to membrane depolarization.
The influence of terminal sprouting on quantal release
from the mammalian NMJs has been investigated in
another context, that of recovery after chronic block of
nerve impulses. Using a cuff containing tetrodotoxin to
block the rat sciatic nerve, Tsujimoto et al. (1990) observed
an increase in quantal content before any sprouting was
detectable. At later times, the quantal content was no
greater at those NMJs where sprouting had occurred
than where it had not. They concluded that sprouting
and increased quantal content are not causally related
in the conditions of their experiments. By implication,
a mechanism must exist by which quantal content can
be raised within the confines of the original NMJ. A
similar conclusion was reached in studies of increased
quantal release in the absence of any enlargement of
the NMJ in myasthenia gravis and an animal model of
it (Plomp et al. 1992, 1995). The mechanism of the
up-regulation of quantal release in these situations is
unknown. It is therefore impossible to know whether a
similar mechanism might be responsible for the recovery
of the original NMJs after exposure to BoNT/A. However,
it should be noted that in these other examples there is no
indication of structural alterations to the proteins involved
in exocytosis, or to the resulting need to replace them, that
characterize the response to BoNT/A.
Changes in synaptic events during recovery. Previous
studies of NMJs blocked by BoNT/A have reported an
increase in the number of spontaneous mEPPs with
abnormally large amplitudes and long time courses
(Thesleff & Molgo, 1983; Kim et al. 1984), sometimes
referred to as ‘giant’ or ‘slow’ mEPPs. Much less has been
reported about the properties of evoked EPPs and EPCs.
While it has been stated that the rise time of individual
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evoked EPPs remained normal during the recovery period
(Kim et al. 1984), evidence has also been presented of a
slowing of the decay phase of EPCs 1 week after exposure to
BoNT/A (Sellin & Thesleff, 1981). In the present study we
observed a striking slowing of the time course of the evoked
responses recorded during recovery. This slowing resulted
from increases in the latency, synaptic delay and the rise
and decay times of the EPPs. These changes reached a peak
just as transmission began to be effective and were largely
reversed when the quantal content was still only 20–30%
of normal. It may be that these changes were missed in
earlier studies which concentrated more on changes in the
first week after exposure to BoNT/A.
The nature of these changes in EPP time course is likely
to be multifactorial. Both the prolonged synaptic delay and
the slower rise time of the EPP suggest alterations of the
release process. These may well be related to recovery from
the effects of the cleavage of SNAP-25 (Sakaba et al. 2005).
In addition, there is evidence that during recovery from
BoNT/A, L- and N-type voltage-gated calcium channels
are present in the nerve terminal along with the P/Q-type
channels normally present (Day et al. 1997; Santafe et al.
2000; Pagani et al. 2004). It is possible that the L- and
N-type channels are not as closely associated with the active
zone (Urbano et al. 2003) as the P/Q-channels and this may
lead to an increase in latency and/or rise time of the EPP.
Little is known about the sequence of events in this process
of nerve terminal maturation or how it is regulated.
On the postsynaptic side, the period of inactivity
imposed by the action of BoNT/A almost certainly results
in reduction of AChE activity (Hall, 1973) at the original
synaptic sites and increase in the expression of γ -AChR
subunits and hence slow, ‘fetal’ AChRs (Klarsfeld &
Changeux, 1985; Goldman et al. 1988; Witzemann et al.
1991; Koltgen et al. 1994; Missias et al. 1996). Both of
these postsynaptic changes would be likely to lead to the
prolongation of the falling phase of the EPP. However,
they would not be expected to have a major impact on
the rising phase. AChE appears at new synaptic sites soon
after the sprouts grow out (Duchen, 1970) and would be
expected to hasten the falling phase of synaptic currents
and potentials at the new sites. How, if at all, the slow
EPPs we observed correspond to the slow mEPPs reported
previously is unclear. Although we found a correlation
between the time courses of EPPs and mEPPs from the
same fibres, the numbers of mEPPs was too small to be
confident of this relationship.
It was particular striking that more than one population
of EPPs could be recorded from some single muscle fibres
(Fig. 10). The very slow rise time of the ‘slow’ components
strongly suggests local variations in the properties of the
nerve terminals. It may be that the various synaptic spots,
potentially both new and old, on a given muscle fibre
acquire ‘mature’ properties at different times. The increase
in quantal content associated with recovery of the ETA
lasts at least 8–10 weeks. Previous studies have shown that
axonal sprouts may continue to grow for a similar length of
time (Juzans et al. 1996a; Santafe et al. 2000). It is therefore
likely that new contacts continue to be made throughout
this period, though possibly at a progressively slower rate
as muscle activity returns to normal. This suggests that
synaptic contacts established both early and late in the
recovery process might coexist on the same muscle fibre,
and might have relatively fast and slow EPPs associated
with them.
By the end of the main recovery process, 3–4 months
after exposure to BoNT/A, the functional properties of
mouse ETA NMJs that we examined had essentially
returned to normal. The observation that the response
to repetitive stimulation is qualitatively similar to that in
untreated mice, showing both rapid transient potentiation
at high frequency followed by depression, suggests that
both calcium dynamics and synaptic vesicle pools in the
motor nerve terminals recover their normal properties
after treatment with BoNT/A. Not enough experiments of
this kind were performed to know whether the differences
between the curves in Fig. 11 represent statistically
significant differences.
Recovery from multiple exposures to BoNT/A
Ours is the only study we are aware of that has
examined systematically the state of neuromuscular trans-
mission after multiple exposures to BoNT/A. Although
the extended duration of these experiments means that
the samples were not large, it is nonetheless clear that very
substantial recovery is possible even after three exposures.
This is consistent with the clinical observations that under-
lie the need for multiple injections to maintain effective
weakening of dystonic muscles (Jankovic & Hallett, 1994).
However, there is a clear indication from our data that
recovery after two and three exposures is slower, and more
variable, than after an initial exposure.
In contrast to the eventual success of functional
recovery, striking structural abnormalities persisted long
after multiple exposures to BoNT/A. This indicates that,
at least in the mouse ETA, an appreciable number of
the new contacts made during initial recovery survive
the withdrawal process that has been noted by previous
authors (Duchen, 1970; de Paiva et al. 1999). Whether
the plasticity of these ‘extended’ nerve branches when
confronted with further exposures to BoNT/A is as great as
when BoNT/A is first given is unclear. It is also important
to note that the animals receiving multiple injections were
generally older when the muscles were examined than
those receiving only one. How, if at all, the ageing process
influences NMJ plasticity remains an important question
for the future.
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
 at University of Newcastle on September 9, 2008 jp.physoc.orgDownloaded from 
3180 A. A. Rogozhin and others J Physiol 586.13
Biological and clinical implications
Our results indicate that recovery of evoked quantal release
can occur in the region of the original NMJ at an early
stage of the response to BoNT/A. In addition, they show
that there are similarities in the sequence of events in
the maturation of the release process at the original NMJ
and at more remote ‘new’ contacts. The structural basis
of the early release we observed from the region of the
original NMJ is not clear. One possibility is that the original
contacts recover more rapidly than previously thought.
Alternatively, or in addition, it may be that new sprouts and
functional contacts are made within the original synaptic
region as well as more remotely. Local remodelling of the
NMJ is well-documented in a number of situations. It
occurs during normal ageing (Barker & Ip, 1966; Arizono
et al. 1984) and is very marked at NMJs on muscle fibres
that regenerate after damage (Duchen et al. 1974; Lyons &
Slater, 1991). Although the molecular basis of this local
plasticity is not understood in detail, up-regulation of
surface adhesion molecules is likely to play a part. In
support of this is the observation that overexpression of
NCAM in mouse muscle leads to sprouting both within
and away from the NMJs (Walsh et al. 2000). Since muscle
inactivity leads to up-regulation of NCAM (Cashman
et al. 1987), it is likely to occur after exposure to BoNT/A
and may therefore play an important part in stimulating
both local and remote sprouting. If, as seems likely from
available evidence (Duchen, 1970; Brown et al. 1980; Frey
et al. 2000), the detailed pattern of recovery differs between
species and muscles, it will be of interest to learn which
factors determine the balance between reinnervation of
the original NMJ and the formation of new, often quite
remote, synaptic contacts in different muscles.
A striking feature of NMJ remodelling is that it often
results in NMJs with abnormal structure but substantially
normal function. This is known to be true in two of the
examples cited above (mdx mice, NCAM up-regulation).
The ability of the NMJ to maintain an adequately
functional state in the face of structural disruption is
further supported by observations of NMJs after multiple
exposures to BoNT/A both in animals, as presented here,
and in humans (Holds et al. 1990) (Pang et al. in pre-
paration). Together with other evidence of the ability of
the mammalian NMJ to regulate quantal output to match
need (e.g. Plomp et al. 1994, 1995), these findings attest to
the remarkable adaptive plasticity of the NMJ. In spite of
its biological importance, almost nothing is known about
the nature of this form of plasticity.
Although we found that NMJs in the mouse ETA could
recover function after multiple exposures to BoNT/A, there
was clear indication that the process eventually became less
effective. Thus, there was an accumulation of structurally
abnormal NMJs and functional recovery was slower after
an initial exposure. These observations suggest that the
NMJ does not return to a fully normal state after repeated
exposure to BoNT/A. This should sound a note of caution
for those using BoNT/A as the basis for clinical and
cosmetic treatments.
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